Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06425090 in Healthy Adults 65-85 Years
NCT02561195Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2015
- Primary completion
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Clostridium difficile vaccine in Clostridioides difficile infection (CDI) (6 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Month 7, Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B at Month 7 and 4 more. Started Jul 2015; status: completed.
02
Drugs
Clostridium difficile vaccine
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02561195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561195.